(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 9 June 2005 (09.06.2005)

PCT

(10) International Publication Number WO 2005/051931 A2

(51) International Patent Classification7:

C07D 261/04

(21) International Application Number:

PCT/IB2004/003893

(22) International Filing Date:

26 November 2004 (26.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/525,347

26 November 2003 (26.11.2003)

- (71) Applicant (for all designated States except US): RAN-BAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru Place, New Delhi, Delhi 110019 (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PALLE, Venkata, P. [IN/IN]; D-011, Oakwood Estate, Akashneem Marg, DLF - Phase - II, Gurgaon, Haryana 122001 (IN). BALACHANDRAN, Sarala [IN/IN]: A-6. National Institute of Immunology, Aruna Asif Ali Marg, New Delhi, Delhi 110067 (IN). GUPTA, Nidhi [IN/IN]; J-160, Vikaspuri, New Delhi, Delhi 110018 (IN). KUKREJA, Gagan [IN/IN]; LD-166, Pitampura, Delhi, Delhi 110088 (IN). KHERA, Manoj, Kumar [IN/IN]; #2682, Inside Kot, Ganaur City, Sonepat, Haryana 131101 (IN). BAREGAMA, Lalit, Kumar [IN/IN]; Chyawan-Bhavan, Adarsh Nagar, Kapasan, Chittorgarh, Rajasthan 312202 (IN). MANDADAPU, Raghuramaiah [IN/IN]; Mandepudi, Amrawati, Guntur, Andhra Pradesh 522018 (IN). RAY, Abhijit [IN/IN]; Sector C-1, Flat No. 1408,

Vasant Kunj, New Delhi, Delhi 110070 (IN). DASTIDAR, Sunanda, Ghose [IN/IN]; B-138, Sarita Vihar, New Delhi, Delhi 110044 (IN).

- (74) Common Representative: RANBAXY LABORATO-RIES LIMITED; c/o DESHMUKH, Jay R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHOSPHODIESTERASE INHIBITORS

(57) Abstract: The present invention relates to isoxazoline derivatives and their analogues, which can be used as phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided.

